Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 212 posts found.

lilly_entrance_web

Lilly’s cancer drug Retsevmo gets UK approval for multiple indications

March 10, 2021
Research and Development Cancer, Eli Lilly, MHRA

The MHRA has granted conditional marketing authorisation for Eli Lilly’s Retsevmo (selpercatinib) as monotherapy for a number of cancer indications.

News
credit_-_daniel_leal-olivas-afp

CHMP recommends Lilly’s bamlanivimab for COVID-19 patients

March 8, 2021
Sales and Marketing COVID-19, EMA, Eli Lilly

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …

News
lilly_entrance_web

Eli Lilly’s diabetes drug tirzepatide reduces blood glucose and weight in Phase III trials

February 18, 2021
Eli Lilly, diabetes

Eli Lilly’s tirzepatide led to significant haemoglobin A1C (HbA1C) and body weight reductions from baseline in adults with type 2 …

News
Eli Lilly front sign

University of Glasgow and Lilly sign £4.6m immunological disease partnership

February 15, 2021
Sales and Marketing Eli Lilly, University of Glasgow, arthritis, fibrosis, lilly, uofg

The University of Glasgow and Eli Lilly and Company have entered into a research collaboration, across four diseases, worth £4.6 …

News
lilly_entrance_web

FDA grants emergency authorisation to Lilly’s COVID-19 antibody combination

February 11, 2021
COVID-19, Eli Lilly

The FDA has granted emergency use authorisation for Eli Lilly’s antibodies bamlanivimab (LY-CoV555) 700mg and etesevimab (LY-CoV016) 1400mg, to be …

News
lilly_building_with_american_flag_web

Lilly’s antibody could reduce COVID-19 risk by 80%, trial shows

January 22, 2021
Medical Communications COVID-19, Eli Lilly

Eli Lilly’s neutralising antibody bamlanivimab significantly reduced the risk of contracting symptomatic coronavirus among residents and staff of long-term care …

News
lilly_building_with_american_flag_web

Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial

January 11, 2021
Sales and Marketing Alzheimer's, Eli Lilly

Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition and daily function in patients …

News
lilly_building_with_american_flag_web

Eli Lilly scoops up gene therapy specialist Prevail Therapeutics for a potential $1.04bn

December 16, 2020
Research and Development, Sales and Marketing Eli Lilly, Prevail, acquisition

Eli Lilly has struck a deal to acquire Prevail Therapeutics in a transaction that could be valued at up to …

News
lilly_entrance_web

Lilly’s tirzepatide generates significant reductions in weight and blood sugar in type 2 diabetes patients

December 10, 2020
Research and Development Eli Lilly, diabetes, tirzepatide

Eli Lilly has announced new data for its glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, showing …

News
lilly_building_with_american_flag_web

NICE recommends Lilly’s Emgality for chronic and episodic migraine

November 18, 2020
Research and Development, Sales and Marketing Eli Lilly, NHS, NICE, UK

Eli Lilly’s Emgality (galcanezumab) is set to become an approved option for the prevention of episodic and chronic migraine on …

News
lilly_building_with_american_flag_web

US reserves 300,000 doses of Lilly’s COVID-19 treatment in $375 million deal

October 28, 2020
Manufacturing and Production, Research and Development, Sales and Marketing COVID-19, Eli Lilly, US, pharma

The US Government has signed a $375 million deal with Eli Lilly to buy 300,000 700mg doses of bamlanivimab, its …

News
lilly_entrance_web

Eli Lilly refutes FDA quality concerns at New Jersey facility producing COVID-19 drug

October 21, 2020
Manufacturing and Production, Research and Development COVID-19, Eli Lilly, FDA, pharma

Eli Lilly has rebutted reports of FDA quality assurance concerns at its manufacturing facility in Branchburg, New Jersey, where it …

News
800px-eli_lilly_corporate_center_indianapolis_indiana_usa_1

Eli Lilly COVID-19 antibody therapy trial paused over safety concerns

October 14, 2020
Research and Development COVID, Eli Lilly, coronavirus

Eli Lilly has stopped enrolling volunteers in clinical trials of its antibody treatment for the novel coronavirus over safety concerns.  …

News
800px-eli_lilly_corporate_center_indianapolis_indiana_usa

Eli Lilly’s antibody COVID-19 therapy reduces virus levels and hospitalisations

October 8, 2020
Manufacturing and Production Eli Lilly, FDA

Eli Lilly is seeking Emergency Use Authorization from the FDA after releasing interim data based on early trial results.

News
lilly_building_with_american_flag_web

Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients, according to new data

September 15, 2020
Manufacturing and Production, Research and Development COVID-19, Eli Lilly, pharma, remdesivir

Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s …

News

Latest content

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024

Cara Therapeutics shares data from part a of notalgia paresthetica trial

June 13, 2024

Tracon shares data from phase 2 trial for glioblastoma treatment

June 12, 2024